Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis

키워드

참고문헌 (78)

1. Saag KG, "Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events", Am J Med, 96, pp.115~123 (1994)
2. Lane NE, "The science and therapy of glucocorticoid-induced bone loss", Endocrinol Metab Clin North Am, 27, pp.465~483 (1998)
3. Van Staa TP, "Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy", Arthritis Rheum, 48, pp.3224~3229 (2003)
4. Steinbuch M, "Oral glucocorticoid use is associated with an increased risk of fracture", Osteoporos Int, 15, pp.323~328 (2004)
5. Angeli A, "High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study", Bone, 39, pp.253~259 (2006)
6. Feldstein AC, "Practice patterns in patients at risk for glucocorticoid-induced osteoporosis", Osteoporos Int, 16, pp.2168~2174 (2005)
7. Salerno A, "Efficacy and safety of steroid use for postoperative pain relief. Update and review of the medical literature", J Bone Joint Surg Am, 88, pp.1361~1372 (2006)
8. Fardet L, "Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study", Medicine (Baltimore), 94, pp.e647~ (2015)
9. Van Staa TP, "Use of oral corticosteroids in the United Kingdom", QJM, 93, pp.105~111 (2000)
10. Van Staa TP, "The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis", Osteoporos Int, 13, pp.777~787 (2002)
11. LoCascio V, "Bone loss in response to long-term glucocorticoid therapy", Bone Miner, 8, pp.39~51 (1990)
12. Kim D, "Glucocorticoids are associated with an increased risk for vertebral fracture in patients with rheumatoid arthritis", J Rheumatol, 45, pp.612~620 (2018)
13. Weinstein RS, "True strength", J Bone Miner Res, 15, pp.621~625 (2000)
14. Leslie WD, "The importance of spectrum bias on bone density monitoring in clinical practice", Bone, 39, pp.361~368 (2006)
15. Seeman E, "Bone quality--the material and structural basis of bone strength and fragility", N Engl J Med, 354, pp.2250~2261 (2006)
16. Buckley L, "2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis", Arthritis Care Res (Hoboken), 69, pp.1095~1110 (2017)
17. Van Staa TP, "A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids", QJM, 98, pp.191~198 (2005)
18. Hall GM, "The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women", Arthritis Rheum, 36, pp.1510~1516 (1993)
19. Laan RF, "Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study", Ann Intern Med, 119, pp.963~968 (1993)
20. Kim SY, "Guidance for development of clinical practice guidelines. ver 1.0", National Evidence-based Healthcare Collaborating Agency, ~ (2011)
21. Grossman JM, "American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis", Arthritis Care Res (Hoboken), 62, pp.1515~1526 (2010)
22. Lekamwasam S, "A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis", Osteoporos Int, 23, pp.2257~2276 (2012)
23. Papaioannou A, "2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary", CMAJ, 182, pp.1864~1873 (2010)
24. Briot K, "2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis", Joint Bone Spine, 81, pp.493~501 (2014)
25. Pereira RM, "Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis", Rev Bras Reumatol, 52, pp.580~593 (2012)
26. Suzuki Y, "Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update", J Bone Miner Metab, 32, pp.337~350 (2014)
27. Rossini M, "Guidelines for the diagnosis, prevention and management of osteoporosis", Reumatismo, 68, pp.1~39 (2016)
28. Brouwers MC, "AGREE II: advancing guideline development, reporting and evaluation in health care", J Clin Epidemiol, 63, pp.1308~1311 (2010)
29. Compston J, "UK clinical guideline for the prevention and treatment of osteoporosis", Arch Osteoporos, 12, pp.43~ (2017)
30. Kanis JA, "Guidance for the adjustment of FRAX according to the dose of glucocorticoids", Osteoporos Int, 22, pp.809~816 (2011)
31. Kaji H, "Glucocorticoid excess affects cortical bone geometry in premenopausal, but not postmenopausal, women", Calcif Tissue Int, 82, pp.182~190 (2008)
32. Fassio A, "The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis", Reumatismo, 68, pp.65~71 (2016)
33. Canalis E, "Glucocorticoid-induced osteoporosis: pathophysiology and therapy", Osteoporos Int, 18, pp.1319~1328 (2007)
34. Sambrook P, "Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin", N Engl J Med, 328, pp.1747~1752 (1993)
35. Boutsen Y, "Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone", J Bone Miner Res, 16, pp.104~112 (2001)
36. Adachi JD, "Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup", J Rheumatol, 23, pp.995~1000 (1996)
37. Buckley LM, "Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial", Ann Intern Med, 125, pp.961~968 (1996)
38. Braun JJ, "Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study", Clin Endocrinol (Oxf), 19, pp.265~273 (1983)
39. Reginster JY, "Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis", Osteoporos Int, 9, pp.75~81 (1999)
40. Okada Y, "Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy", J Rheumatol, 35, pp.2249~2254 (2008)
41. Saag KG, "Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group", N Engl J Med, 339, pp.292~299 (1998)
42. Adachi JD, "Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial", Arthritis Rheum, 44, pp.202~211 (2001)
43. Lems WF, "Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial", Osteoporos Int, 17, pp.716~723 (2006)
44. Stoch SA, "Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial", J Rheumatol, 36, pp.1705~1714 (2009)
45. Tee SI, "Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study", Arch Dermatol, 148, pp.307~314 (2012)
46. Wallach S, "Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy", Calcif Tissue Int, 67, pp.277~285 (2000)
47. Yamada S, "Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients", Yakugaku Zasshi, 127, pp.1491~1496 (2007)
48. Cohen S, "Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study", Arthritis Rheum, 42, pp.2309~2318 (1999)
49. Reid DM, "Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial", Lancet, 373, pp.1253~1263 (2009)
50. Langdahl BL, "Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status", Osteoporos Int, 20, pp.2095~2104 (2009)
51. Saag KG, "Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study", Lancet Diabetes Endocrinol, 6, pp.445~454 (2018)
52. Candelas G, "Calcium supplementation and kidney stone risk in osteoporosis: a systematic literature review", Clin Exp Rheumatol, 30, pp.954~961 (2012)
53. Lewis JR, "The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials", J Bone Miner Res, 30, pp.165~175 (2015)
54. de Nijs RN, "Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis", N Engl J Med, 355, pp.675~684 (2006)
55. Yilmaz L, "Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids", Rheumatol Int, 20, pp.65~69 (2001)
56. Eastell R, "Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients", Osteoporos Int, 11, pp.331~337 (2000)
57. Reid DM, "Risedronate increases bone density and reduces vertebral fracture risk with in one year in men on corticosteroid therapy", Calcif Tissue Int, 69, pp.242~247 (2001)
58. Reid DM, "Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study", J Bone Miner Res, 15, pp.1006~1013 (2000)
59. Hakala M, "Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial", Scand J Rheumatol, 41, pp.260~266 (2012)
60. Sambrook PN, "Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate", Bone, 50, pp.289~295 (2012)
61. Durie BG, "Osteonecrosis of the jaw and bisphosphonates", N Engl J Med, 353, pp.99~102 (2005)
62. Lazarovici TS, "Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients", J Oral Maxillofac Surg, 67, pp.850~855 (2009)
63. review: bisphosphonates and osteonecrosis of the jaws, "Ann Intern Med", 2006, 753~761
64. Giusti A, "Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features", Bone, 48, pp.966~971 (2011)
65. Edwards MH, "Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?", Osteoporos Int, 21, pp.701~703 (2010)
66. Goh SK, "Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution", J Bone Joint Surg Br, 89, pp.349~353 (2007)
67. Ing-Lorenzini K, "Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital", Drug Saf, 32, pp.775~785 (2009)
68. Kwek EB, "An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?", Injury, 39, pp.224~231 (2008)
69. Shane E, "Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 29, pp.1~23 (2014)
70. Lane NE, "Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial", J Clin Invest, 102, pp.1627~1633 (1998)
71. Saag KG, "Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial", Arthritis Rheum, 60, pp.3346~3355 (2009)
72. Saag KG, "Teriparatide or alendronate in glucocorticoid-induced osteoporosis", N Engl J Med, 357, pp.2028~2039 (2007)
73. Dore RK, "Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates", Ann Rheum Dis, 69, pp.872~875 (2010)
74. Mok CC, "Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial", Ann Rheum Dis, 70, pp.778~784 (2011)
75. Patlas N, "Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats", Teratology, 60, pp.68~73 (1999)
76. Levy S, "Pregnancy outcome following in utero exposure to bisphosphonates", Bone, 44, pp.428~430 (2009)
77. Ornoy A, "The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment", Reprod Toxicol, 22, pp.578~579 (2006)
78. Camacho PM, "American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016", Endocr Pract, 22, pp.1~42 (2016)

관련 논문AI추천